• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.

    5/9/25 1:06:25 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNTC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    Benitec Biopharma Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001

    (Title of Class of Securities)


    08205P209

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    08205P209


    1Names of Reporting Persons

    Franklin Resources, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,415,130.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,415,130.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,415,130.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    16.3 %
    12Type of Reporting Person (See Instructions)

    HC, CO

    Comment for Type of Reporting Person:  The number of shares beneficially owned and the percentage of the class that it represents includes 1,554,404 shares of Common Stock issuable on the exercise of warrants.


    SCHEDULE 13G

    CUSIP No.
    08205P209


    1Names of Reporting Persons

    Charles B. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    08205P209


    1Names of Reporting Persons

    Rupert H. Johnson, Jr.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    08205P209


    1Names of Reporting Persons

    Franklin Advisers, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,415,130.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,415,130.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,415,130.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    16.3 %
    12Type of Reporting Person (See Instructions)

    IA, CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Benitec Biopharma Inc.
    (b)Address of issuer's principal executive offices:

    3940 Trust Way, Hayward, CA 94545
    Item 2. 
    (a)Name of person filing:

    (i): Franklin Resources, Inc. (ii): Charles B. Johnson (iii): Rupert H. Johnson, Jr. (iv): Franklin Advisers, Inc.
    (b)Address or principal business office or, if none, residence:

    (i), (ii), (iii) and (iv): One Franklin Parkway San Mateo, CA 94403-1906
    (c)Citizenship:

    (i): Delaware (ii) and (iii): USA (iv): California
    (d)Title of class of securities:

    Common Stock, par value $0.0001
    (e)CUSIP No.:

    08205P209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    4,415,130
    (b)Percent of class:

    16.3%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Franklin Resources, Inc.: 0 Charles B. Johnson: 0 Rupert H. Johnson, Jr.: 0 Franklin Advisers, Inc.: 4,415,130

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    Franklin Resources, Inc.: 0 Charles B. Johnson: 0 Rupert H. Johnson, Jr.: 0 Franklin Advisers, Inc.: 4,415,130

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The clients of the Investment Management Subsidiaries, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, the securities reported herein. Franklin Biotechnology Discovery Fund, a series of Franklin Strategic Series, an investment company registered under the Investment Company Act of 1940, has an interest in 1,529,335 shares, or 5.6% of the class of securities reported herein and Franklin Biotechnology Discovery Fund, a sub-fund of Franklin Templeton Investment Funds, a Luxembourg Registered SICAV has an interest in 2,885,722 shares, or 10.6% of the class of securities reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Attached Exhibit C
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Franklin Resources, Inc.
     
    Signature:/s/Thomas C. Mandia
    Name/Title:Thomas C. Mandia, Assistant Secretary of Franklin Resources, Inc.
    Date:05/08/2025
     
    Charles B. Johnson
     
    Signature:/s/Thomas C. Mandia
    Name/Title:Attorney in Fact for Charles B. Johnson pursuant to Power of Attorney
    Date:05/08/2025
     
    Rupert H. Johnson, Jr.
     
    Signature:/s/Thomas C. Mandia
    Name/Title:Attorney in Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney
    Date:05/08/2025
     
    Franklin Advisers, Inc.
     
    Signature:/s/Thomas C. Mandia
    Name/Title:Thomas C. Mandia, Assistant Secretary of Franklin Advisers, Inc.
    Date:05/08/2025

    Comments accompanying signature:  LIMITED POWERS OF ATTORNEY FOR SECTION 13 AND 16 REPORTING OBLIGATIONS FOR CHARLES B. JOHNSON AND RUPERT H, JOHNSON, JR. (incorporated by reference to Schedule 13G/A No. 4 filed on January 27, 2025) LIMITED POWER OF ATTORNEY FOR SECTION 13 REPORTING OBLIGATIONS Know all by these presents, that we Franklin Templeton Investment Funds (the "Issuer"). an entity organized and existing in the Grand Duchy of Luxembourg and having our registered office at 8A rue Albert Borschette, L-1246 Luxembourg, in the person of Gregory Johnson and Vijay Advani, Directors of the Issuer, hereby makes, constitutes and appoints each of Lori Weber and Kimberly Novotny, each acting individually as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to: (1)prepare, execute, acknowledge, deliver and file Schedules 13D and 13G (including any amendments thereto or any related documentation) with the United States Securities and Exchange Commission, any national securities exchanges and Franklin Resources, Inc., a Delaware corporation (the "Reporting Entity"), as considered necessary or advisable under Section 13 of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the "Exchange Act"); and (2)perform any and all other acts which in the discretion of such attorney in fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing. The undersigned acknowledges that: (1) this Limited Power of Attorney authorizes, but does not require, each such attorney in fact to act in their discretion on information provided to such attorney in fact without independent verification of such information; (2) any documents prepared and/or executed by either such attorney in fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney in fact, in his or her discretion, deems necessary or desirable; (3) neither the Reporting Entity nor either of such attorneys in fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act or (ii) any liability of the undersigned for any failure to comply with such requirements; and (4) this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including without limitation the reporting requirements under Section 13 of the Exchange Act. The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney in fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney. This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney in fact. IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 13th day of October, 2015. For and on behalf of Franklin Templeton Investment Funds /s/Gregory Johnson Director /s/Vijay Advani Director
    Exhibit Information

    Exhibit A: Joint Filing Agreement Exhibit B: Item 4 Ownership Exhibit C: Item 7 Identification and Classification of Subsidiaries Exhibit A: JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other of the attached statement on Schedule 13G and to all amendments to such statement and that such statement and all amendments to such statement are made on behalf of each of them. IN WITNESS WHEREOF, the undersigned have executed this agreement on the date of the signing of this filing. Franklin Resources, Inc. Charles B. Johnson Rupert H. Johnson, Jr. Franklin Advisers, Inc. By: /s/THOMAS C. MANDIA Assistant Secretary of Franklin Resources, Inc. Attorney-in-Fact for Charles B. Johnson pursuant to Power of Attorney Attorney-in-Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney Assistant Secretary of Franklin Advisers, Inc. Acknowledgment pursuant to Rule 13d-1(b)(1)(iii) Franklin Strategic Series on behalf of Franklin Biotechnology Discovery Fund By: /s/ALISON E. BAUR Vice President and Assistant Secretary of Franklin Strategic Series Franklin Templeton Investment Funds on behalf of Franklin Biotechnology Discovery Fund /s/ KIMBERLY D. HARPER Attorney-in-Fact for Franklin Templeton Investment Funds pursuant to Power of Attorney attached to this Schedule 13G Named changed from KIMBERLY H. NOVOTNY. Exhibit B: Item 4 Ownership The securities reported herein are beneficially owned by one or more open or closed end investment companies or other managed accounts that are investment management clients of investment managers that are direct and indirect subsidiaries (each, an "Investment Management Subsidiary" and, collectively, the "Investment Management Subsidiaries") of Franklin Resources Inc. ("FRI"), including the Investment Management Subsidiaries listed in this Item 4. When an investment management contract (including a sub advisory agreement) delegates to an Investment Management Subsidiary investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, FRI treats the Investment Management Subsidiary as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies otherwise. Accordingly, each Investment Management Subsidiary reports on Schedule 13G that it has sole investment discretion and voting authority over the securities covered by any such investment management agreement, unless otherwise noted in this Item 4. As a result, for purposes of Rule 13d-3 under the Act, the Investment Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners of the securities reported in this Schedule 13G. Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 34 -9538 (January 12, 1998) (the "1998 Release") relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from each other. The voting and investment powers held by each of FRI's affiliates whose ownership of securities is disaggregated from that of FRI in accordance with the 1998 Release ("FRI Disaggregated Affiliates") are exercised independently from FRI and from all other Investment Management Subsidiaries (FRI, its affiliates and the Investment Management Subsidiaries other than FRI Disaggregated Affiliates are collectively, "FRI Aggregated Affiliates"). Furthermore, internal policies and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand, FRI establish informational barriers that prevent the flow among, on the one hand, FRI Disaggregated Affiliates (including preventing the flow between such entities), and, on the other hand, the FRI Aggregated Affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, FRI Disaggregated Affiliates report the securities over which they hold investment and voting power separately from the FRI Aggregated Affiliates for purposes of Section 13 of the Act. Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") may each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI (see FRI's Proxy Statement-Stock Ownership of Certain Beneficial Owners). FRI and the Principal Shareholders may be deemed to be, for purposes of Rule 13d-3 under the Act, the beneficial owners of securities held by persons and entities for whom or for which FRI subsidiaries provide investment management services. The number of shares that may be deemed to be beneficially owned and the percentage of the class of which such shares are a part are reported in Items 9 and 11 of the cover page for FRI. FRI, the Principal Shareholders and each of the Investment Management Subsidiaries disclaim any pecuniary interest in any of such securities. In addition, the filing of this Schedule 13G on behalf of the Principal Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be construed as an admission that any of them is, and each of them disclaims that it is, the beneficial owner, as defined in Rule 13d-3, of any of the securities reported in this Schedule 13G. FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries believe that they are not a "group" within the meaning of Rule 13d-5 under the Act and that they are not otherwise required to attribute to each other the beneficial ownership of the securities held by any of them or by any persons or entities for whom or for which the Investment Management Subsidiaries provide investment management services. EXHIBIT C: Item 7 Identification and Classification of Subsidiaries Franklin Advisers, Inc.: Item 3 Classification: 3(e)

    Get the next $BNTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNTC

    DatePrice TargetRatingAnalyst
    12/16/2024$28.00Buy
    H.C. Wainwright
    12/13/2024$30.00Outperform
    Robert W. Baird
    10/16/2024$35.00Outperform
    Oppenheimer
    9/12/2024$17.00Buy
    Guggenheim
    7/22/2024$13.00Outperform
    Leerink Partners
    6/13/2024$30.00Overweight
    Piper Sandler
    2/17/2022$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BNTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $527,174 worth of shares (47,520 units at $11.09) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      12/26/24 4:28:03 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

      HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.00 and each pre-funded warra

      3/25/25 8:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

      -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301 for Subject 3, with Subject 3 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Positive Interim Clinical Study Results

      3/19/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma to Participate in Upcoming Conferences in March

      HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences. TD Cowen 45th Annual Health Care ConferenceDate: March 5, 2025Time of Presentation: 9:50 AM to 10:20 AM EST Format: Presentation & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Leerink Partners Global Healthcare Conference 2025Date: March 12

      2/26/25 7:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Suvretta Capital Management, Llc bought $211,736 worth of shares (16,497 units at $12.83) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      4/2/25 4:37:02 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Suvretta Capital Management, Llc bought $11,700,000 worth of shares (900,000 units at $13.00) (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/28/25 4:51:41 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Buchi J Kevin gifted 103,626 shares and received a gift of 103,626 shares, decreasing direct ownership by 100% to 284 units (SEC Form 4)

      4 - Benitec Biopharma Inc. (0001808898) (Issuer)

      3/13/25 4:43:09 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Financials

    Live finance-specific insights

    See more
    • Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

      -Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

      2/14/25 8:10:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update

      -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no

      11/14/24 4:30:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benitec Biopharma Announces Updated Investor Webcast Information

      -Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,

      10/14/24 6:00:00 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      12/6/24 1:47:28 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Benitec Biopharma Inc.

      SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/18/24 4:36:00 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

      SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      11/14/24 1:37:20 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Benitec Biopharma Inc.

      SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

      5/9/25 1:06:25 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Benitec Biopharma Inc.

      8-K - Benitec Biopharma Inc. (0001808898) (Filer)

      3/28/25 5:13:22 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Benitec Biopharma Inc.

      SCHEDULE 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

      3/28/25 4:50:57 PM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Benitec Biopharma with a new price target

      H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

      12/16/24 6:46:22 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Benitec Biopharma with a new price target

      Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

      12/13/24 7:25:56 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Benitec Biopharma with a new price target

      Oppenheimer initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $35.00

      10/16/24 7:20:22 AM ET
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

      HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

      7/1/24 7:00:00 AM ET
      $BHVN
      $BNTC
      Biotechnology: Pharmaceutical Preparations
      Health Care